NodThera is focused on developing innovative therapies that target the NLRP3 inflammasome, a key driver of inflammation linked to various chronic diseases. Their approach is grounded in extensive scientific research that identifies the NLRP3 inflammasome as a critical upstream activator of pro-inflammatory cytokines such as IL-1β and IL-18. By inhibiting this inflammasome, NodThera aims to address the root causes of chronic inflammatory diseases, including obesity, cardiovascular conditions, and neurodegenerative disorders. The company is advancing a portfolio of differentiated small molecules designed to penetrate tissues effectively, including the brain, thereby offering potential treatments that can overcome the limitations of existing biologics.

NodThera's pipeline includes several promising candidates, such as NT-0796, which is engineered to deliver therapeutic payloads directly to immune cells involved in inflammation. This molecule is currently undergoing clinical trials for conditions like Parkinson's disease and cardiovascular risks in obese patients. Other candidates, like NT-0249 and NT-0150, are designed to be brain-penetrant and target neuroinflammatory diseases. The company's innovative chemistry and strategic focus on NLRP3 inhibition position it to make significant advancements in treating chronic inflammatory diseases, potentially improving the lives of millions of patients with limited treatment options.

United States

NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We’re building a dynamic team of people across our offices in Cambridge, UK; Seattle, WA; and Boston, MA; all united by our shared ambition, enthusiasm, and creativity.

NodThera

Company Details